EQT will pay €46.50 for Qiagen. Thermo Fisher's €43 failed in 2020.
EQT's €10.8bn Qiagen bid is 8.1% above the offer that lapsed at 47% acceptance in 2020. The bar is lower on paper, and the fund paying has not yet started.
EQT's €10.8bn Qiagen bid is 8.1% above the offer that lapsed at 47% acceptance in 2020. The bar is lower on paper, and the fund paying has not yet started.
Microsoft last gave a Copilot seat count in July. This quarter it gave multiples with no base, and a price list that now includes a meter.
Fundraising fell 17% on a year ago and 68% on the second quarter. The fee-bearing capital growth rate sits on a restated base.
FS KKR spent about $69m buying back stock at roughly 61% of its reported book value, as NAV has fallen 12.5% this year and income is down 21%.
Distributable earnings per share rose 17% on a fivefold jump in carry. Fee related earnings fell 6%, and twelve-month inflows are down 15%.